Herrmann B L, Schatz H, Pfeiffer A
Universitätsklinikum Essen, Zentrum für Innere Medizin, Abteilung für Endokrinologie.
Med Klin (Munich). 1998 Nov 15;93(11):651-5. doi: 10.1007/BF03044876.
Acarbose, a pseudo-tetrasaccharid, inhibits intestinal alpha-glucosidases, effects a reduction of postprandial hyperglycemia and is particularly used in the treatment of patients with type-2 diabetes mellitus. The aim of the study is to analyse by a continuous blood glucose measurement the acute effect of acarbose after a carbohydrate loading and during a 12 hours period.
We examined 10 patients with type-2 diabetes mellitus (mean age 59.2 +/- 3.79, HbA1 9.2 +/- 0.26%) treated with sulfonylureas and/or insulin after a carbohydrate meal and 12 hours during daytime, to test whether the first application of acarbose influences the mean blood glucose or the blood glucose amplitudes. Four measurements were enrolled using a portable continuous blood glucose sensor (Glucosensor, unitec Ulm). A measurement after a carbohydrate loading (Fresubin, 500 kcal, 69 g carbohydrate) with 100 mg acarbose (Glucobay) was followed by a 12-hour measurement during daytime with 3 x 100 mg acarbose and standard diet. These measurements were repeated without acarbose.
After a carbohydrate loading, the mean blood glucose level (AUC 44,320 +/- 10,660 with acarbose vs. 61,390 +/- 12,590 without acarbose; mean + SD; p = 0.004) decreased by 28%. During daytime blood glucose levels were not significantly decreased (165.7 +/- 50.3 mg/dl vs 183.7 + 67.4 mg/dl; p = 0.1) although the postprandial blood glucose amplitudes after the 3 meals were reduced significantly (85.90 +/- 24.6 mg/dl vs 106.5 +/- 20.5 mg/dl; p = 0.02).
Continuous blood glucose monitoring indicated that acarbose diminished mean blood glucose levels after a carbohydrate loading in patients with type-2 diabetes mellitus, but not during 12 hours of standard diet, although blood glucose amplitudes decreased. Long-term improvements of metabolism by acarbose may therefore be related to the reduction of blood glucose amplitudes which is likely to reduce toxic effects of glucose on islet cell function.
阿卡波糖是一种假四糖,可抑制肠道α-葡萄糖苷酶,降低餐后高血糖,尤其用于治疗2型糖尿病患者。本研究的目的是通过连续血糖监测分析碳水化合物负荷后及12小时内阿卡波糖的急性效应。
我们检查了10例接受磺脲类药物和/或胰岛素治疗的2型糖尿病患者(平均年龄59.2±3.79岁,糖化血红蛋白9.2±0.26%),在进食碳水化合物餐后及白天12小时内,以测试首次应用阿卡波糖是否会影响平均血糖或血糖波动幅度。使用便携式连续血糖传感器(葡萄糖传感器,德国乌尔姆联合技术公司)进行四次测量。在摄入含100毫克阿卡波糖(拜糖平)的碳水化合物负荷(能全素,500千卡,69克碳水化合物)后进行一次测量,随后在白天进行12小时测量,期间服用3次100毫克阿卡波糖并采用标准饮食。在不服用阿卡波糖的情况下重复这些测量。
碳水化合物负荷后,平均血糖水平(服用阿卡波糖时曲线下面积为44320±10660,未服用阿卡波糖时为61390±12590;均值±标准差;p = 0.004)下降了28%。白天血糖水平虽未显著下降(165.7±50.3毫克/分升对183.7±67.4毫克/分升;p = 0.1),但三餐后餐后血糖波动幅度显著降低(85.90±24.6毫克/分升对106.5±20.5毫克/分升;p = 0.02)。
连续血糖监测表明,阿卡波糖可降低2型糖尿病患者碳水化合物负荷后的平均血糖水平,但在标准饮食的12小时内未降低,尽管血糖波动幅度有所下降。因此,阿卡波糖对代谢长期的改善作用可能与血糖波动幅度的降低有关,这可能会减少葡萄糖对胰岛细胞功能的毒性作用。